Eloxx Pharmaceuticals (NASDAQ: ELOX) up 168% - what, again? Why?

Eloxx Pharmaceuticals (NASDAQ: ELOX) stock is up 168% on the day. ELOX stock rose 94% in the trading day, another 39% in the aftermarket. The most immediate reaction to this is what, again? For back in May we had a very similar 200% in a day jump in the Elox stock price. Which was followed by a 2 month slide back to the original starting price. So while the price moves were something that could be successfully traded this was not something we'd want to have invested in. Investment here meaning a buy and hold strategy, trading being either side of a price movement. Now it's not true that history repeats itself but in the absence of any particularly new information we'd probably conclude that it does echo.

Back those two months we said about Eloxx: “There is no special news from the company to explain this price movement. What there is is a very small market capitalisation (some $7 million) being driven by a wave of activity and no more than that. The question really becomes whether someone is deliberately driving this - what is called a pump and dump - or whether it's just one of those things - a momentum trade perhaps. But given that there seems to be no objective reason for it we'd expect it not to persist.   

“As we say, there's nothing objectively wrong with Eloxx but it's not that darn good either. Therefore we expect the price to settle back down again.”

We were right too -  ELOX stock took two months to get there but after that period it was back where it had started. 

Eloxx Pharmaceuticals stock price from NASDAQ

We also pointed out that there's real work going on within Eloxx, even what seems to be good work. But it's very early stage and there's no guarantee of success at all.

There's nothing at Edgar (the SEC's information site) or elsewhere in announcements from the company. We do have an analyst report from Oppenheimer with a target price of $55 for ELOX stock. But that's it and that sort of analysis is very speculative in itself. For to get to those sorts of numbers it is necessary to forecast whether a treatment is going to make it through FDA approval. Which, well, let's say stock analysts aren't always right about that.

At which point we'll repeat our earlier analysis. Eloxx is doing good work and it may come good at some point. But there's nothing in any information source we can see which justifies a 160% price change in this past day. We'll therefore run with the idea that - as two months ago - this is speculation getting ahead of reality. We'd expect, on the balance of probabilities, to see the ELOX stock price come back down again.